Free Trial

SAB Biotherapeutics (SABS) News Today

SAB Biotherapeutics logo
$1.19 -0.06 (-4.80%)
As of 01:11 PM Eastern
Craig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum
Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)
SAB Biotherapeutics (SABS) Gets a Buy from Oppenheimer
SAB BIO Appoints Lucy To as Chief Financial Officer
SAb Biotherapeutics Rebrands as SAB BIO
SAB Leaps on Completing Latest Cohort
SAB Biotherapeutics Provides SAB-142 Trial Update
Remove Ads
Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.

SABS Media Mentions By Week

SABS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SABS
News Sentiment

-0.80

0.57

Average
Medical
News Sentiment

SABS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SABS Articles
This Week

11

1

SABS Articles
Average Week

Remove Ads
Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SABS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners